Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01333163
Other study ID # VEKRM 29414
Secondary ID
Status Completed
Phase N/A
First received April 8, 2011
Last updated December 14, 2011
Start date May 2011
Est. completion date December 2011

Study information

Verified date December 2011
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: The Regional Committee on Biomedical Research EthicsDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Healthy young men

Exclusion Criteria:

- Any chronic diseases

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Biological:
Human GLP-1 (7-36) amide
2 hour IV infusion, 1,5pmol/min/kg.
Isotone NaCl
2 hours IV infusion.

Locations

Country Name City State
Denmark Klinisk Institut, Afd. MEA, Aarhus Sygehus, NBG Aarhus C

Sponsors (2)

Lead Sponsor Collaborator
Jeppe Skov Novo Nordisk A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glomerular Filtration Rate Every 20 minutes for 6 hours No
See also
  Status Clinical Trial Phase
Completed NCT02437838 - Optimizing Drug Doses in Critically Ill N/A